Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25115571 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Livhuwani P Nendouvhada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science and Innovation/Mintek Nanotechnology Innovation Centre, Biolabels Research Node, Department of Biotechnology, University of the…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Phytotherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease, is a steatotic liver disease associated with metabolic syndrome (MetS), especially obesity, hypertension, diabetes, hyperlipidemia, and hypertriglyceridemia. MASLD in 43–44% of patients can progress to metabolic dysfunction-associated steatohepatitis (MASH), and 7–30% of these cases will progress to liver scarring (cirrhosis). To date, the mechanism of MASLD and its progression is not completely understood and there were no therapeutic strategies specifically tailored for MASLD/MASH until March 2024. The conventional antiobesity and antidiabetic pharmacological approaches used to reduce the progression of MASLD demonstrated favorable peripheral outcomes but insignificant effects on liver histology. Alternatively, phyto-synthesized metal-based nanoparticles (MNPs) are now being explored in the treatment of various liver diseases due to their unique bioactivities and reduced bystander effects. Although phytonanotherapy has not been explored in the clinical treatment of MASLD/MASH, MNPs such as gold NPs (AuNPs) and silver NPs (AgNPs) have been reported to improve metabolic processes by reducing blood glucose levels, body fat, and inflammation. Therefore, these actions suggest that MNPs can potentially be used in the treatment of MASLD/MASH and related metabolic diseases. Further studies are warranted to investigate the feasibility and efficacy of phytonanomedicine before clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Science and Innovation/Mintek Nanotechnology Innovation Centre, Biolabels Research Node, Department of Biotechnology, University of the Western Cape, Bellville 7535, South Africa.
- Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg 7505, South Africa.
- Health Platform, Advanced Materials Division, Mintek, Randburg 2194, South Africa.
- Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville 7535, South Africa.
ORCID-Profile: Nicole R S Sibuyi, Samantha Meyer, Abram M Madiehe, Mervin Meyer, Kwazikwakhe B Gabuza
Zitieren
APA
Nendouvhada, L. P., Sibuyi, N. R. S., Fadaka, A. O., Meyer, S., Madiehe, A. M., Meyer, M., & Gabuza, K. B. (2024). Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115571
Vancouver
Nendouvhada LP, Sibuyi NRS, Fadaka AO, Meyer S, Madiehe AM, Meyer M, et al. Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25115571
BibTeX
@article{Nendouvhada2024,
author = {Nendouvhada, Livhuwani P and Sibuyi, Nicole R S and Fadaka, Adewale O and Meyer, Samantha and Madiehe, Abram M and Meyer, Mervin and Gabuza, Kwazikwakhe B},
title = {Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25115571}
}
EUVIMED